EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetic Variation in Hydrochlorothiazide Response‐Related Genes Among Hypertensive Individuals in Soweto, South Africa

Kudakwashe Nyamupangedengu iD, David Twesigomwe iD, Andrew May iD, Collen Masimirembwa iD, Neil Martinson, Ziyaad Waja iD, Matebogo Letutu, Michèle Ramsay iD

Clinical and Translational Science · 2025-07 · 18 (7)

DOI: 10.1111/cts.70302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 18.07.2025. Verfasst von Kudakwashe Nyamupangedengu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Hydrochlorothiazide, Hypertension, Antihypertensive Agents, Pharmacogenomic Variants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: South African Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Africa bears the largest burden of morbidity and mortality from hypertension (HT) and related cardiovascular diseases. Thiazide diuretics, including hydrochlorothiazide (HCTZ), are the most prescribed hypertension medicines globally due to their cost effectiveness and minimal side effects. However, studies investigating the genetic variation in HCTZ‐related genes and their effect on drug response have been mainly conducted in European, American, and Asian populations. This study aimed to examine genetic variation in HCTZ response‐related genes among newly diagnosed hypertensives from Soweto, South Africa, irrespective of the treatment approach, and to assess its potential impact on medication response. Using targeted NGS on 364 newly diagnosed hypertensives with at least one follow‐up visit, we identified 1258 unique variants in 16 key HCTZ response genes. Among these, 89 were novel variants, of which 12 were protein‐altering, including 8 predicted to be deleterious. Association analyses with 882 independent variants revealed that carriers of the intronic variant rs1025450259 in GNB3 had significantly greater reduction in BP compared to other patients on heterogeneous treatment strategies, but no significant associations were detected in the subset of individuals treated with HCTZ monotherapy only ( n = 103). For variants previously associated with HCTZ response, we did not replicate prior associations (e.g., rs2611316 in ALDH1A2 ) but highlight important allele frequency differences across global populations. Despite the limitations, the study outcomes support the need for larger, controlled trials to assess genetic influences on HT treatment outcomes, advancing personalized medicine for African populations. This research further underscores the importance of pharmacogenetic studies in continental African populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrochlorothiazideHypertensionAntihypertensive AgentsPharmacogenomic VariantsHumansSouth AfricaFemaleMaleMiddle AgedPolymorphism, Single NucleotideAdultBlood PressureAgedTreatment Outcome

Substanzen

HydrochlorothiazideAntihypertensive Agents

Autor:innen und Institutionen

  • Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Biomolecular Sciences, School of Life Science, Pharmacy, and Chemistry, Kingston University London, London, UK.
  • African Institute of Biomedical Science & Technology, Harare, Zimbabwe.
  • Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Kudakwashe Nyamupangedengu, David Twesigomwe, Andrew May, Collen Masimirembwa, Ziyaad Waja, Michèle Ramsay

Förderung

  • South African Medical Research Council

Zitieren

APA

Nyamupangedengu, K., Twesigomwe, D., May, A., Masimirembwa, C., Martinson, N., Waja, Z., Letutu, M., & Ramsay, M. (2025). Genetic Variation in Hydrochlorothiazide Response‐Related Genes Among Hypertensive Individuals in Soweto, South Africa. Clinical and Translational Science, 18(7). https://doi.org/10.1111/cts.70302

Vancouver

Nyamupangedengu K, Twesigomwe D, May A, Masimirembwa C, Martinson N, Waja Z, et al. Genetic Variation in Hydrochlorothiazide Response‐Related Genes Among Hypertensive Individuals in Soweto, South Africa. Clinical and Translational Science. 2025;18(7). doi:10.1111/cts.70302

BibTeX
@article{Nyamupangedengu2025,
  author = {Nyamupangedengu, Kudakwashe and Twesigomwe, David and May, Andrew and Masimirembwa, Collen and Martinson, Neil and Waja, Ziyaad and Letutu, Matebogo and Ramsay, Michèle},
  title = {Genetic Variation in Hydrochlorothiazide Response‐Related Genes Among Hypertensive Individuals in Soweto, South Africa},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {7},
  doi = {10.1111/cts.70302}
}
Kostenlos starten →